Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$205.12
+1.2%
$197.50
$153.58
$218.66
$362.85B0.615.68 million shs6.48 million shs
Allergan plc stock logo
AGN
Allergan
$193.02
$190.89
$114.27
$202.21
$63.50B1.24.01 million shs12.44 million shs
BXRX
Baudax Bio
$0.02
+7.4%
$0.02
$0.01
$3.47
$1.14M1.57281,029 shs310,800 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$89.18
+1.8%
$91.92
$81.04
$134.63
$225.27B0.3511.01 million shs12.39 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.20
+0.8%
$26.06
$24.48
$31.54
$142.93B0.6138.88 million shs32.32 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-2.31%-1.89%+16.41%+12.64%
Allergan plc stock logo
AGN
Allergan
0.00%0.00%0.00%0.00%0.00%
BXRX
Baudax Bio
0.00%0.00%0.00%0.00%0.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.56%-3.31%-9.34%-32.41%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-3.83%-4.65%-4.61%-9.19%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.5161 of 5 stars
2.53.03.33.93.52.51.3
Allergan plc stock logo
AGN
Allergan
N/AN/AN/AN/AN/AN/AN/AN/A
BXRX
Baudax Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.35.05.03.92.83.33.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9866 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.92
Moderate Buy$211.453.09% Upside
Allergan plc stock logo
AGN
Allergan
0.00
N/AN/AN/A
BXRX
Baudax Bio
0.00
N/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1231.33% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9226.67% Upside

Current Analyst Ratings Breakdown

Latest BXRX, ABBV, PFE, AGN, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.00
3/4/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.00
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.44$15.16 per share13.53$1.90 per share107.96
Allergan plc stock logo
AGN
Allergan
$16.09B3.95$36.70 per share5.26$177.28 per share1.09
BXRX
Baudax Bio
$1.27M0.90N/AN/A($14.93) per share0.00
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.51$3.09 per share28.82$14.85 per share6.01
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.25$3.95 per share6.38$15.81 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4085.4714.671.627.59%296.28%12.65%4/25/2025 (Estimated)
Allergan plc stock logo
AGN
Allergan
-$5.27B$17.64N/A10.651.63-15.44%8.46%5.31%N/A
BXRX
Baudax Bio
-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7313.259.010.7726.67%45.35%17.36%4/24/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.878.320.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest BXRX, ABBV, PFE, AGN, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2025N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.51N/AN/AN/A$12.91 billionN/A
4/24/2025N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
1/31/2025Q4 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.20%+6.04%273.33%53 Years
Allergan plc stock logo
AGN
Allergan
$2.961.53%N/A16.78%N/A
BXRX
Baudax Bio
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.63%+5.73%48.14%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.83%+2.50%121.99%16 Years

Latest BXRX, ABBV, PFE, AGN, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Allergan plc stock logo
AGN
Allergan
0.31
1.01
0.84
BXRX
Baudax Bio
N/A
0.07
0.07
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Allergan plc stock logo
AGN
Allergan
83.91%
BXRX
Baudax Bio
9.05%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Allergan plc stock logo
AGN
Allergan
0.08%
BXRX
Baudax Bio
0.10%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Allergan plc stock logo
AGN
Allergan
17,400329.00 millionN/AOptionable
BXRX
Baudax Bio
952.46 million52.41 millionNot Optionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. stock logo
Bcwm LLC Invests $4.26 Million in Pfizer Inc. (NYSE:PFE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$205.12 +2.40 (+1.18%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$203.69 -1.43 (-0.70%)
As of 03/28/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Allergan stock logo

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Baudax Bio NASDAQ:BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$89.18 +1.58 (+1.80%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$89.15 -0.03 (-0.03%)
As of 03/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$25.14 -0.07 (-0.26%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.